Delivery Order SPE2DB22D1106-SPE2DB25FFBA9
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide a pharmaceutical product called VIMPAT 10 MG/ML SOLUTION 200ML. The contract, valued at $1,292.15, has an ultimate completion date of April 12, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of up to $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of VIMPAT 200 MG tablets in a quantity of 60 units, with a contract ceiling value of $1,089.82. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract has an ultimate completion date of July 28, 2025, and AmerisourceBergen will perform this work from its corporate office location in...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of VIMPAT 10 MG/ML SOLUTION 200ML. The contract has a ceiling value of $1,172.13 and a period of performance through June 10, 2025. The contract is not set aside and was awarded on a competitive basis. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The Defense Logistics Agency awarded Amerisourcebergen Drug Corporation a $445 firm fixed price delivery order for 4561423111 VIMPAT 10 MG/ML SOLUTION 200ML. As the prime contractor, Amerisourcebergen will deliver the pharmaceutical product to a location in Conshohocken, Pennsylvania, under a one-day period of performance between July 6-7, 2023. The Defense Logistics Agency is a combat logistics support agency within the Department of Defense responsible for worldwide logistics support. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VIMPAT 10 mg/ml solution in 200 ml containers, with a ceiling value of $1,105.15. It is a firm fixed-price delivery order contract with a period of performance ending on July 16, 2025. The contract is not set-aside for any specific business type. AmerisourceBergen Drug Corp holds a...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,567.64, is for the delivery of VIMPAT 10 MG/ML SOLUTION 200ML, a pharmaceutical product. The award is a delivery order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract, valued at $1,181.88, is for the delivery of VIMPAT 10 MG/ML SOLUTION 200ML, a specialty medication. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of April 14, 2025. This award is not associated with a set-aside program. The contract appears to be part of a larger Indefinite Delivery...
- This delivery order, awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corporation, has a potential value of five hundred one dollars. The firm fixed price order is for VIMPAT 10 MG/ML solution in 200ML bottles, with an anticipated completion date of September 21, 2023. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. The Defense Logistics Agency manages the global supply...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide VIMPAT 10 MG/ML SOLUTION 200ML. The contract has a completion date of February 16, 2024 and a potential value of $1,688.80. Amerisourcebergen Drug Corp, a for-profit organization, is the prime contractor on this award, which is not associated with any set-aside designations. The contract is part of Amerisourcebergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of VIMPAT 100 mg at a ceiling value of $1,089.84 under a firm fixed price contract type. This award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFBA9Delivery Order
The Defense Logistics Agency awarded a $1,455.99 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for VIMPAT 10 mg/mL Solution in 200 mL quantities. This firm fixed price order, with an ultimate completion date of August 4, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was awarded without a set-aside designation through competitive procurement, and performance will occur at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply relationship with the Defense Logistics Agency, which includes a substantial $999,999,999.00 indefinite delivery vehicle (SPE2DX) extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a broad range of medications and medical commodities to support military healthcare programs globally. VIMPAT, an anti-seizure medication, represents the type of specialized pharmaceutical product the company routinely delivers to support Defense Health Agency and other federal healthcare systems through its established prime vendor arrangement with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/1/25 |